Literature DB >> 10739326

Review of incidence studies of tardive dyskinesia associated with typical antipsychotics.

W M Glazer1.   

Abstract

Unless researchers make an organized effort, patients with tardive dyskinesia are difficult to study and easily lost to follow up. Because there is no treatment for tardive dyskinesia, investigators are obliged to study the natural history of the disorder and identify risk and prognostic factors to further understand pathophysiologic mechanisms and to guide prevention and treatment efforts. Abundant variability exists among incidence studies of tardive dyskinesia, depending to some extent on design issues. In this article, the design concepts of incidence and prevalence studies are described, along with results, methodological problems, and identified risk factors in various tardive dyskinesia incidence studies involving the use of typical antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739326

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

1.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

2.  Extrapyramidal side-effects of antipsychotics in a randomised trial.

Authors:  Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-10       Impact factor: 9.319

3.  The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.

Authors:  Jair de Jesus Mari; Mauricio S Lima; Anna Niccolai Costa; Neusa Alexandrino; Salomao Rodrigues-Filho; Irismar Reis de Oliveira; Gary D Tollefson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

4.  Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.

Authors:  Jeroen P F Koning; Diederik E Tenback; Jim van Os; André Aleman; René S Kahn; Peter N van Harten
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

Review 5.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.

Authors:  Spiridon Konitsiotis; Christos Tsironis; Dimitrios N Kiortsis; Angelos Evangelou
Journal:  Psychopharmacology (Berl)       Date:  2006-03-04       Impact factor: 4.530

7.  Motor Disturbance in ASD: A Pilot Study Showing Hypokinetic Behavior?

Authors:  M A L Mostert-Kerckhoffs; A E Willems; D E Tenback; J P Koning; P Van Harten; W G Staal
Journal:  J Autism Dev Disord       Date:  2020-02

8.  Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia.

Authors:  Xiang Yang Zhang; Da Chun Chen; Ling Yan Qi; Fang Wang; Mei Hong Xiu; Song Chen; Gui Ying Wu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

Review 9.  Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Hanna Bergman; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17

10.  Tardive and spontaneous dyskinesia incidence in the general population.

Authors:  Ray M Merrill; Joseph L Lyon; Paul M Matiaco
Journal:  BMC Psychiatry       Date:  2013-05-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.